<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656665</url>
  </required_header>
  <id_info>
    <org_study_id>ThirdGuangzhouMU</org_study_id>
    <nct_id>NCT04656665</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Aspirin on Preventing Pre-eclampsia</brief_title>
  <official_title>The Effectiveness of Low-dose Aspirin on Preventing Pre-eclampsia in High-risks Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the effectiveness of low-dose aspirin on preventing pre-eclampsia in&#xD;
      high-risks pregnant women by comparing the incidence of pre-eclampsia and pregnancy outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently，low-dose aspirin is a commonly used drug to prevent pre-eclampsia. Many guidelines&#xD;
      recommend starting low-dose aspirin in early pregnancy in high-risks pregnant women. However,&#xD;
      the applicable population and use method of aspirin are still controversial in clinical&#xD;
      practice. This study will explore the effectiveness and use method of low-dose aspirin by&#xD;
      comparing the incidence of pre-eclampsia and pregnancy outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pre-eclampsia</measure>
    <time_frame>1 year</time_frame>
    <description>Record the number of pre-eclampsia in each group and compare whether there are statistical differences in the incidence of each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>1 year</time_frame>
    <description>Record the number of preterm in each group and compare whether there are statistical differences in the incidence of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal growth restriction</measure>
    <time_frame>1 year</time_frame>
    <description>Record the number of FGR in each group and compare whether there are statistical differences in the incidence of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental abruption 4/5000 Placental abruption</measure>
    <time_frame>1 year</time_frame>
    <description>Record the number of placental abruption in each group and compare whether there are statistical differences in the incidence of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>1 year</time_frame>
    <description>Record the number of postpartum hemorrhage in each group and compare whether there are statistical differences in the incidence of each group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take 75mg of aspirin daily in tihis group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take 100mg of aspirin daily in this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not taking aspirin in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy</description>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_label>75mg</arm_group_label>
    <other_name>Acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-55 years&#xD;
&#xD;
          -  Gestational age between 12-20 weeks of pregnancy&#xD;
&#xD;
          -  High risk of developing pre-eclampsia&#xD;
&#xD;
               -  At least one of the following risk factors: Pre-eclampsia in a previous pregnancy&#xD;
                  , Multiple pregnancy，Diabetes Mellitus(Type 1 or 2), Chronic Hypertension，Renal&#xD;
                  disease, Autoimmune disease.&#xD;
&#xD;
               -  At least two of the following risk factors: Primiparity，Pre-pregnancy Body Mass&#xD;
                  Index ≥28kg/m2, Age ≥35 years, Family members have a history of pre-eclampsia.&#xD;
&#xD;
          -  Maternal informed conset obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to aspirin therapy (including but not limited to allergy and high&#xD;
             bleeding risk)&#xD;
&#xD;
          -  Patient with known intention to terminate pregnancy&#xD;
&#xD;
          -  Fetal abnormalities detected （including but not limited to major fetal malformation&#xD;
             and FGR）&#xD;
&#xD;
          -  Severe heart, liver, renal disease who can not burden the experiment&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  Being in another drug experiment within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fang He, Dr.</last_name>
    <phone>+86020-81292532</phone>
    <email>hefangjnu@126.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-eclampsia, Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

